Arcutis Biotherapeutics, Inc. (ARQT) Misses Q1 EPS by 4c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $105.4 million versus the consensus estimate of $103.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15